Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis

Pulmonary Pharmacology and Therapeutics

Volumn 25, Issue 1, 2012, Pages 94-98

  Nicolau, David P ^a   Sutherland, Christina ^a   Winget, Donna ^b   Baughman, Robert P ^b  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

AECB; Fluoroquinolone; Levofloxacin; Penetration; Pharmacodynamic; Pharmacokinetic

Indexed keywords

LEVOFLOXACIN; UREA;

ACUTE EXACERBATION OF CHRONIC BRONCHITIS; ADULT; AREA UNDER THE CURVE; ARTICLE; BRONCHOSCOPY; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DILUTION; DRUG ERUPTION; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; MALE; OPEN STUDY; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; URTICARIA; VEIN PUNCTURE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BRONCHITIS, CHRONIC; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKOCYTE COUNT; MACROPHAGES, ALVEOLAR; MALE; MIDDLE AGED; OFLOXACIN; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY MUCOSA; UREA; YOUNG ADULT;

EID: 84856794419     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2011.12.007     Document Type: Article

References (19)

1. Levaquin [package insert] 2010, Ortho McNeil Pharmaceutical, Inc, Raritan, New Jersey.
2. Martinez F.J., Grossman R.F., Zadeikis A.C., Fisher A.C., Walker K., Ambruzs M.E., et al. Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750mg. Eur Respir J 2005, 25:1001-1010.
3. Dunbar L.M., Wunderink R.G., Habib M.P., Smith L.G., Tennenberg A.M., Khashab M.M., et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003, 37:752-760.
4. File T.M. Anew dosing paradigm: high-dose, short-course fluoroquinolone therapy for community-acquired pneumonia. Clin Cornerstone 2003, 3(suppl):S1-S9.
5. Chien S.C., Wong F.A., Fowler C.L., Callery-D'Amico S.V., Williams R.R., Nayak R., et al. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-mg and 1-gram doses of levofloxacin in healthy volunteers. Antimicrob Agents Chemother 1998, 42:885-888.
6. Gotfried M.H., Danziger L.H., Rodvold K.A. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 2001, 119:1114-1122.
7. Rodvold K.A., Danziger L.H., Gotfried M.H. Steady-state and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob Agents Chemother 2003, 47:2450-2457.
8. Capitano B., Mattoes H.M., Shore E., O'Brien A., Braman S., Sutherland C., et al. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest 2004, 125:965-973.
9. Conte J.E., Golden J.A., McIver M., Little E., Zurlinden E. Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. Int J Antimicrob Agents 2007, 30:422-427.
10. Boselli E., Breilh D., Rimmele T., Djabarouti S., Saux M.C., Chassard D., et al. Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. Crit Care Med 2005, 33:104-109.
11. Anthonisen N.R., Manfreda J., Warren C.P.W., Hershfield E.S., Harding G.K., Nelson N.A. Antibiotic therapy in exacerbations of chronic pulmonary disease. Ann Intern Med 1987, 106:196-204.
12. Onyeji C.O., Bui K.Q., Owens R.C., Nicolau D.P., Quintiliani R., Nightingale C.H. Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicemia. Int J Antimicrob Agents 1999, 12:107-114.
13. Rennard S.I., Basset G., Lecossier D., O'Donnell K.M., Pinkston P., Martin P.G., et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as a marker of dilution. JAppl Physiol 1986, 60:532-538.
14. Johnson J.D., Hand W.L., Francis J.B., King-Thompson N., Corwin R.W. Antibiotic uptake by alveolar macrophages. JLab Clin Med 1980, 85:429-439.
15. Sahm D.F. Resistance issues and community-acquired respiratory infections. Clin Cornerstone 2003, 3(suppl):S1-S9.
16. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antimicrobial dosing of mice and men. Clin Infect Dis 1998, 226:1-12.
17. Cazzola M., Matera M.G., Donnarumma G., Tufano M.A., Sanduzzi A., Marchetti F., et al. Pharmacodynamics of levofloxacin in patients with acute exacerbations of chronic bronchitis. Chest 2005, 128:2093-2098.
18. Cazzola M., Matera M.G., Tufano M.A., Catalanotti P., Polverino M., Cantoni V., et al. Pulmonary disposition of lomefloxacin in patients with acute exacerbation of chronic obstructive pulmonary disease. A multiple-dose study. JChemother 2001, 13:407-412.
19. Baldwin D.R., Wise R., Andrews J.M., Gill M., Honeybourne D. Comparative bronchoalveolar concentrations of ciprofloxacin and lomefloxacin following oral administration. Respir Med 1993, 87:595-601.